Cargando…

ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19

Angiotensin converting enzyme-2 (ACE2) is a multifunctional transmembrane protein recently recognised as the entry receptor of the virus causing COVID-19. In the renin–angiotensin system (RAS), ACE2 cleaves angiotensin II (Ang II) into angiotensin 1-7 (Ang 1-7), which is considered to exert cellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Koichi, Takeshita, Hikari, Rakugi, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687025/
https://www.ncbi.nlm.nih.gov/pubmed/33231620
http://dx.doi.org/10.1042/CS20200486
_version_ 1783613446720323584
author Yamamoto, Koichi
Takeshita, Hikari
Rakugi, Hiromi
author_facet Yamamoto, Koichi
Takeshita, Hikari
Rakugi, Hiromi
author_sort Yamamoto, Koichi
collection PubMed
description Angiotensin converting enzyme-2 (ACE2) is a multifunctional transmembrane protein recently recognised as the entry receptor of the virus causing COVID-19. In the renin–angiotensin system (RAS), ACE2 cleaves angiotensin II (Ang II) into angiotensin 1-7 (Ang 1-7), which is considered to exert cellular responses to counteract the activation of the RAS primarily through a receptor, Mas, in multiple organs including skeletal muscle. Previous studies have provided abundant evidence suggesting that Ang 1-7 modulates multiple signalling pathways leading to protection from pathological muscle remodelling and muscle insulin resistance. In contrast, there is relatively little evidence to support the protective role of ACE2 in skeletal muscle. The potential contribution of endogenous ACE2 to the regulation of Ang 1-7-mediated protection of these muscle pathologies is discussed in this review. Recent studies have suggested that ACE2 protects against ageing-associated muscle wasting (sarcopenia) through its function to modulate molecules outside of the RAS. Thus, the potential association of sarcopenia with ACE2 and the associated molecules outside of RAS is also presented herein. Further, we introduce the transcriptional regulation of muscle ACE2 by drugs or exercise, and briefly discuss the potential role of ACE2 in the development of COVID-19.
format Online
Article
Text
id pubmed-7687025
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-76870252020-12-04 ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19 Yamamoto, Koichi Takeshita, Hikari Rakugi, Hiromi Clin Sci (Lond) Molecular Bases of Health & Disease Angiotensin converting enzyme-2 (ACE2) is a multifunctional transmembrane protein recently recognised as the entry receptor of the virus causing COVID-19. In the renin–angiotensin system (RAS), ACE2 cleaves angiotensin II (Ang II) into angiotensin 1-7 (Ang 1-7), which is considered to exert cellular responses to counteract the activation of the RAS primarily through a receptor, Mas, in multiple organs including skeletal muscle. Previous studies have provided abundant evidence suggesting that Ang 1-7 modulates multiple signalling pathways leading to protection from pathological muscle remodelling and muscle insulin resistance. In contrast, there is relatively little evidence to support the protective role of ACE2 in skeletal muscle. The potential contribution of endogenous ACE2 to the regulation of Ang 1-7-mediated protection of these muscle pathologies is discussed in this review. Recent studies have suggested that ACE2 protects against ageing-associated muscle wasting (sarcopenia) through its function to modulate molecules outside of the RAS. Thus, the potential association of sarcopenia with ACE2 and the associated molecules outside of RAS is also presented herein. Further, we introduce the transcriptional regulation of muscle ACE2 by drugs or exercise, and briefly discuss the potential role of ACE2 in the development of COVID-19. Portland Press Ltd. 2020-11 2020-11-24 /pmc/articles/PMC7687025/ /pubmed/33231620 http://dx.doi.org/10.1042/CS20200486 Text en © 2020 The Author(s). https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the .
spellingShingle Molecular Bases of Health & Disease
Yamamoto, Koichi
Takeshita, Hikari
Rakugi, Hiromi
ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19
title ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19
title_full ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19
title_fullStr ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19
title_full_unstemmed ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19
title_short ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19
title_sort ace2, angiotensin 1-7 and skeletal muscle: review in the era of covid-19
topic Molecular Bases of Health & Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687025/
https://www.ncbi.nlm.nih.gov/pubmed/33231620
http://dx.doi.org/10.1042/CS20200486
work_keys_str_mv AT yamamotokoichi ace2angiotensin17andskeletalmusclereviewintheeraofcovid19
AT takeshitahikari ace2angiotensin17andskeletalmusclereviewintheeraofcovid19
AT rakugihiromi ace2angiotensin17andskeletalmusclereviewintheeraofcovid19